GSK’s manufacturing sites in Singapore will use 100% renewable energy by 2025

Anna Brown

News Reporter

GSK said it is on track to convert its global manufacturing sites into using renewable electricity, with its facilities in Singapore becoming the latest to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GSK’s manufacturing sites in Singapore will use 100% renewable energy by 2025

Anna Brown

News Reporter

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

GSK’s man­u­fac­tur­ing sites in Sin­ga­pore will use 100% re­new­able en­er­gy by 2025

Anna Brown

News Reporter

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

GSK’s manufacturing sites in Singapore will use 100% renewable energy by 2025

Applied Therapeutics' rare disease drug gets a CRL

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy